Tecovirimat Does Not Shorten Mpox Lesion Duration, Lower Mortality Among Children And Adults With Clade I Mpox In DRC, Trial Finds

MedPage Today (10/18, Kahn) reported, “The antiviral drug tecovirimat (Tpoxx) failed to shorten the duration of mpox lesions or lower mortality among children and adults with clade I mpox in the Democratic Republic of the Congo (DRC), according to results from the randomized, placebo-controlled PALM007 trial.” Among “hospitalized patients with mpox, lesion resolution took a median of 7 days with tecovirimat compared with 8 days with placebo (competing-risks HR 1.13, 95% CI 0.97-1.31, P=0.14), and mortality was 1.7% in both groups by day 58 after randomization, reported” researchers at IDWeek.